AAP
VRTX icon

Ardsley Advisory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Ardsley Advisory Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-150,000
Closed -$22.8M – 175
2017
Q3 		$22.8M Buy
+150,000
New +$22.6M 3.03% 7

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Ardsley Advisory Partners's VRTX Position: Q2 2026 in Review

Ardsley Advisory Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 15,000 shares worth $7.45M. The stake represents 0.78% of the portfolio and ranks #43 among its holdings. This is a return to the name: Ardsley Advisory Partners previously reported a position in VRTX as recently as Q1 2021.

Ardsley Advisory Partners first reported a position in VRTX in Q2 2016 and has held it in 16 quarters since. The position peaked at $15M in Q1 2021. 597 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ardsley Advisory Partners held 15,000 shares of Vertex Pharmaceuticals worth $7.45M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Ardsley Advisory Partners position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.78% of Ardsley Advisory Partners's portfolio in Q2 2026, its #43 holding.
  • Ardsley Advisory Partners first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 16 quarters since.
  • Ardsley Advisory Partners's Vertex Pharmaceuticals position peaked at $15M in Q1 2021.
  • 597 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.